Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C1381
http://purl.obolibrary.org/obo/NCIT_C1381
|
|---|---|
| Preferred Name | Irinotecan Hydrochloride |
| Definitions |
The hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | The hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent. |
|---|---|
| prefLabel | Irinotecan Hydrochloride
|
| label | Irinotecan Hydrochloride
|
| PDQ_Closed_Trial_Search_ID | 41714
|
| code | C1381
|
| Has_Target | |
| prefixIRI | NCIT:C1381
|
| in_subset |
See more
See less
|
| Display_Name | Irinotecan Hydrochloride
|
| Preferred_Name | Irinotecan Hydrochloride
|
| FDA_UNII_Code | 042LAQ1IIS
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C33H38N4O6.HCl.3H2O
|
| Maps_To | Irinotecan Hydrochloride
|
| CAS_Registry | 136572-09-3
|
| NCI_Drug_Dictionary_ID | 41714
|
| Legacy Concept Name | Irinotecan
|
| Has_Free_Acid_Or_Base_Form | |
| type | |
| ALT_DEFINITION | A drug used alone or with other drugs to treat colon cancer or rectal cancer that has spread to other parts of the body or has come back after treatment with fluorouracil. It is also being studied in the treatment of other types of cancer. Camptosar blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 41714
|
| Accepted_Therapeutic_Use_For | State IVB Cervical cancer; Colorectal cancer; Esophageal cancer; Gastric cancer; Non-small cell lung cancer; Small cell lung cancer
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0594375
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |